NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · SENS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Senseonics Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Senseonics Holdings, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.49. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Senseonics Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.400.0% vs estimate | $6.26M+12.72% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | -$0.40-1,233.33% vs estimate | $8.30M+4.43% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.80-33.33% vs estimate | $4.26M+4.54% vs estimate |
|---|
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $14.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$79.93+$1.31 (+1.67%)
DexCom, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.67% below the high.
$152.50+$3.57 (+2.4%)
Insulet Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.03% below the high.
$19.25+$0.04 (+0.21%)
MiniMed Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.2% below the high.
$19.79+$0.11 (+0.56%)
Tandem Diabetes Care, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.25% below the high.
$17.58-$0.27 (-1.51%)
Beta Bionics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.25% below the high.
